Integrated genome and transcriptome sequencing identifies a novel form of hybrid and aggressive prostate cancer

Next‐generation sequencing is making sequence‐based molecular pathology and personalized oncology viable. We selected an individual initially diagnosed with conventional but aggressive prostate adenocarcinoma and sequenced the genome and transcriptome from primary and metastatic tissues collected prior to hormone therapy. The histology‐pathology and copy number profiles were remarkably homogeneous, yet it was possible to propose the quadrant of the prostate tumour that likely seeded the metastatic diaspora. Despite a homogeneous cell type, our transcriptome analysis revealed signatures of both luminal and neuroendocrine cell types. Remarkably, the repertoire of expressed but apparently private gene fusions, including C15orf21:MYC, recapitulated this biology. We hypothesize that the amplification and over‐expression of the stem cell gene MSI2 may have contributed to the stable hybrid cellular identity. This hybrid luminal‐neuroendocrine tumour appears to represent a novel and highly aggressive case of prostate cancer with unique biological features and, conceivably, a propensity for rapid progression to castrate‐resistance. Overall, this work highlights the importance of integrated analyses of genome, exome and transcriptome sequences for basic tumour biology, sequence‐based molecular pathology and personalized oncology. Copyright © 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

[1]  S. Varambally,et al.  Induced Chromosomal Proximity and Gene Fusions in Prostate Cancer , 2009, Science.

[2]  C. Hoogenraad,et al.  The CASPR2 cell adhesion molecule functions as a tumor suppressor gene in glioma , 2010, Oncogene.

[3]  Jie Zhang,et al.  Nuclear Receptor-Induced Chromosomal Proximity and DNA Breaks Underlie Specific Translocations in Cancer , 2009, Cell.

[4]  Ute Moog,et al.  Mutations in the SHANK2 synaptic scaffolding gene in autism spectrum disorder and mental retardation , 2010, Nature Genetics.

[5]  Raghu Kalluri,et al.  Fibroblasts in cancer , 2006, Nature Reviews Cancer.

[6]  Faraz Hach,et al.  Comrad: detection of expressed rearrangements by integrated analysis of RNA-Seq and low coverage genome sequence data , 2011, Bioinform..

[7]  D. Berney,et al.  Androgen-induced TMPRSS2:ERG fusion in nonmalignant prostate epithelial cells. , 2010, Cancer research.

[8]  Joon-ha Ok,et al.  Clinical implications of neuroendocrine differentiation in prostate cancer , 2007, Prostate Cancer and Prostatic Diseases.

[9]  A. Flesken-Nikitin,et al.  Prostate cancer associated with p53 and Rb deficiency arises from the stem/progenitor cell-enriched proximal region of prostatic ducts. , 2007, Cancer research.

[10]  Lee T. Sam,et al.  Transcriptome Sequencing to Detect Gene Fusions in Cancer , 2009, Nature.

[11]  K. Leong,et al.  Generation of a prostate from a single adult stem cell , 2008, Nature.

[12]  Liang Cheng,et al.  Multifocal prostate cancer: biologic, prognostic, and therapeutic implications. , 2010, Human pathology.

[13]  O. Franco,et al.  Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma , 2010, Oncogene.

[14]  Xiaobing Fu,et al.  The single-macro domain protein LRP16 is an essential cofactor of androgen receptor. , 2008, Endocrine-related cancer.

[15]  Süleyman Cenk Sahinalp,et al.  deFuse: An Algorithm for Gene Fusion Discovery in Tumor RNA-Seq Data , 2011, PLoS Comput. Biol..

[16]  Steven J. M. Jones,et al.  Alternative expression analysis by RNA sequencing , 2010, Nature Methods.

[17]  John T. Wei,et al.  Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression , 2011, Nature Biotechnology.

[18]  Helen Piontkivska,et al.  Analysis of gene expression in prostate cancer epithelial and interstitial stromal cells using laser capture microdissection , 2010, BMC Cancer.

[19]  Jiaoti Huang,et al.  Identification of a Cell of Origin for Human Prostate Cancer , 2010, Science.

[20]  M. Cantile,et al.  Neuroendocrine Differentiation in Prostate Cancer: From Lab to Bedside , 2007, Urologia Internationalis.

[21]  Fatima Al-Shahrour,et al.  Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia , 2010, Nature Medicine.

[22]  Ming-Fong Lin,et al.  Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells. , 2007, Endocrine-related cancer.

[23]  Lior Pachter,et al.  Exon-Level Microarray Analyses Identify Alternative Splicing Programs in Breast Cancer , 2010, Molecular Cancer Research.

[24]  E. McLaughlin,et al.  The RNA-binding protein Musashi is required intrinsically to maintain stem cell identity. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[25]  M. Stratton.  Exploring the Genomes of Cancer Cells: Progress and Promise , 2011, Science.

[26]  L. Bourguignon,et al.  Hyaluronan-mediated CD44 Interaction with RhoGEF and Rho Kinase Promotes Grb2-associated Binder-1 Phosphorylation and Phosphatidylinositol 3-Kinase Signaling Leading to Cytokine (Macrophage-Colony Stimulating Factor) Production and Breast Tumor Progression* , 2003, Journal of Biological Chemistry.

[27]  Ryan D. Morin,et al.  Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution , 2009, Nature.

[28]  Vladimir Makarenkov,et al.  T-REX: reconstructing and visualizing phylogenetic trees and reticulation networks , 2001, Bioinform..

[29]  Jun Luo,et al.  Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis , 2008, Modern Pathology.

[30]  Thomas D. Wu,et al.  Deep RNA sequencing analysis of readthrough gene fusions in human prostate adenocarcinoma and reference samples , 2011, BMC Medical Genomics.

[31]  S. Smith,et al.  Heterogeneity of genomic fusion of BCR and ABL in Philadelphia chromosome-positive acute lymphoblastic leukemia. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[32]  M. Shen,et al.  Revisiting the concept of cancer stem cells in prostate cancer , 2011, Oncogene.

[33]  S. Cullheim,et al.  Netrin G-2 ligand mRNA is downregulated in spinal motoneurons after sciatic nerve lesion , 2010, Neuroreport.

[34]  C. Morrissey,et al.  Prostate epithelial cell differentiation and its relevance to the understanding of prostate cancer therapies. , 2005, Clinical science.

[35]  R. Durbin,et al.  Mapping Quality Scores Mapping Short Dna Sequencing Reads and Calling Variants Using P

, 2022 .

[36]  W. Linehan,et al.  Fumarate Hydratase Deficiency in Renal Cancer Induces Glycolytic Addiction and Hypoxia-Inducible Transcription Factor 1α Stabilization by Glucose-Dependent Generation of Reactive Oxygen Species , 2009, Molecular and Cellular Biology.

[37]  S. Lakhani,et al.  Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression. , 1999, Cancer research.

[38]  J. Maguire,et al.  Integrative analysis of the melanoma transcriptome. , 2010, Genome research.

[39]  S. Dhanasekaran,et al.  Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer , 2007, Nature.

[40]  N. Hayward,et al.  Identification of ARHGEF17, DENND2D, FGFR3, and RB1 mutations in melanoma by inhibition of nonsense‐mediated mRNA decay , 2008, Genes, chromosomes & cancer.

[41]  R. Cardiff,et al.  Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer. , 2008, The American journal of pathology.

[42]  Guangyu Wu,et al.  Rab8 Interacts with Distinct Motifs in α2B- and β2-Adrenergic Receptors and Differentially Modulates Their Transport* , 2010, The Journal of Biological Chemistry.

[43]  K. Pienta,et al.  Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors. , 2011, Genome research.

[44]  F. Hormozdiari,et al.  Comrad : a novel algorithmic framework for the integrated analysis of RNA-Seq and WGSS data , 2011 .

[45]  R. Montironi,et al.  ERG–TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin , 2011, Modern Pathology.

[46]  P. Humphrey,et al.  Molecular Characterization of a Metastatic Neuroendocrine Cell Cancer Arising in the Prostates of Transgenic Mice* 210 , 2002, The Journal of Biological Chemistry.

[47]  Ken Chen,et al.  Use of whole-genome sequencing to diagnose a cryptic fusion oncogene. , 2011, JAMA.

[48]  C. Sander,et al.  Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.

[49]  N. Nemoto,et al.  Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. , 2004, European urology.

[50]  S. Raghavan,et al.  How does DNA break during chromosomal translocations? , 2011, Nucleic acids research.

[51]  Takahiro Ito,et al.  Regulation of myeloid leukemia by the cell fate determinant Musashi , 2010, Nature.

[52]  D. Hudson,et al.  Epithelial stem cells in human prostate growth and disease , 2004, Prostate Cancer and Prostatic Diseases.

[53]  Li Ding,et al.  Identification of a novel TP53 cancer susceptibility mutation through whole-genome sequencing of a patient with therapy-related AML. , 2011, JAMA.

[54]  Wei Li,et al.  Recurrent chimeric RNAs enriched in human prostate cancer identified by deep sequencing , 2011, Proceedings of the National Academy of Sciences.